The FDA has granted approval to the University of Texas Health Science Center at Houston (UTHealth) for its coronary flow reserve quantification software, cfrQuant, which will be sold by Positron.
The cfrQuant software was developed under the guidance of K. Lance Gould, MD, and his colleagues at the Weatherhead PET Imaging Center of the UTHealth Medical School, with contributions of software segments from Positron.
Westmont, Ill.-based Positron said it will distribute and support cfrQuant to its U.S. cardiac PET customers, under a licensing agreement with UTHealth. The cfrQuant software has been approved for use with 82Rb-chloride and 13N-ammonia. Gould has reportedly recused himself of receiving royalties in support of academic programs.
"The capacity of non-invasive PET for quantitative myocardial perfusion using cfrQuant parallels the use of invasive, pressure-based fractional flow reserve for assessing physiologic stenosis severity as a guide to management and revascularization procedures," Gould said in a statement.